GENELUX Corp
GNLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001231457
In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $29.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by GENELUX Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 7 filings
- 4 insiders, $194.3K in total
- Insiders trading
- 4
- Net value
- −$194.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for GENELUX Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cappello Joseph | Chief Technical Officer | 318,480 | Sep 2, 2026 | 6 |
| Zindrick Thomas | President and CEO | 1,226,427 | Sep 2, 2026 | 6 |
| Yu Tony | Chief Scientific Officer | 258,688 | Sep 2, 2026 | 6 |
| Smither John W | Director | 91,403 | Jul 2, 2026 | 2 |
| Tyree James L | Director | 96,483 | Jun 18, 2026 | 1 |
| Groen Eric | General Counsel | 233,957 | Jun 18, 2026 | 1 |
| Mirabelli Mary | Director | 102,693 | Jun 18, 2026 | 1 |
| Thomas John | Director | 501,193 | Jun 18, 2026 | 4 |
| Pulisic Matthew | Chief Financial Officer | 278,906 | Jun 18, 2026 | 1 |
| Smalling Ralph | Head of Regulatory | 67,611 | Jun 4, 2026 | 4 |
| Litten Jason | Chief Medical Officer | – | Jan 7, 2026 | 1 |
| Ryder Sean | General Counsel | 47,621 | May 13, 2025 | 0 |
| Zak Lourie S. | Chief Financial Officer | 82,452 | Dec 20, 2024 | 0 |
| Scigalla Paul | Chief Medical Officer | – | Oct 21, 2024 | 0 |
| Szalay Aladar | 10% Owner | 599,821Indirect | Sep 13, 2024 | 0 |
| Jewett Caroline | Head of Quality | 16,174 | Jul 8, 2024 | 0 |
| Samuelson Doug | Vice President, Finance | 2,303 | Sep 12, 2023 | 0 |
| Zhang Qian | Associate VP, Research | 139,333 | May 2, 2023 | 0 |
| Woodward Gabe | Director | 4,186 | May 2, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing) | Jan 26 | 5 daysLate | Zhang QianAssociate VP, Research | PPurchase | +200 | $6.25 | +$1.25K | New position200 after |